ASP7517
- Generic Name
- ASP7517
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Phase 1
Completed
- Conditions
- Advanced MalignanciesAdvanced Cancer
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04837196
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Iowa Hospitals, Iowa City, Iowa, United States
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04079296
- Locations
- 🇺🇸
Memorial Healthcare System-West, Pembroke Pines, Florida, United States
🇺🇸City of Hope, Duarte, California, United States
🇯🇵Site JP81005, Nagoya, Aichi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath